miR-596通过调控细胞存活与死亡影响黑色素瘤生长
黑色素瘤中miR-596常缺失且低表达,低表达与更差总生存相关。过表达miR-596可抑制MAPK/ERK信号、增殖、迁移和侵袭并促进凋亡。机制上miR-596直接靶向MEK1及抗凋亡蛋白MCL1和BCL2L1,提示其可作为治疗候选和预后因子。
要点
- 黑色素瘤中miR-596低表达,且与更差总生存相关。
- miR-596过表达抑制MAPK/ERK信号及增殖、迁移、侵袭并促进凋亡。
- miR-596直接靶向MEK1、MCL1和BCL2L1。
核心结论
- miR-596通过靶向MEK1负调控MAPK/ERK信号,并通过靶向MCL1和BCL2L1调控凋亡,可能成为黑色素瘤治疗候选和预后因子。
研究设计与样本
- 研究比较黑色素瘤样本与组织痣中miR-596表达,并行Kaplan-Meier曲线分析总生存。
- 在黑色素瘤细胞中进行miR-596过表达,检测MAPK/ERK信号、增殖、迁移、侵袭和凋亡。
- 通过实验鉴定miR-596在黑色素瘤细胞中的直接靶点为MEK1、MCL1和BCL2L1。
主要发现
- TCGA-Assembler显示miR-596在大量黑色素瘤样本中缺失。
- 黑色素瘤中miR-596水平低于组织痣。
- 低miR-596表达与更差总生存相关。
- miR-596过表达抑制MAPK/ERK信号、细胞增殖、迁移和侵袭,并增加黑色素瘤细胞凋亡。
- miR-596在黑色素瘤细胞中直接靶向MEK1、MCL1和BCL2L1。
临床怎么用
- miR-596低表达可作为黑色素瘤预后不良的候选生物标志物。
- 恢复miR-596表达或抑制MEK1/MCL1/BCL2L1轴是潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Tumors grow because cancer cells lack the ability to balance cell survival and death signaling pathways. miR-596, a microRNA located at the 8p23.3 locus, has been shown by the TCGA-Assembler to be deleted in a significant number of melanoma samples. Here, we also validated the low levels of miR-596 in melanoma compared to tissue nevi, and Kaplan-Meier curve analysis revealed that low miR-596 expression was associated with worse overall survival. Moreover, we showed that miR-596 overexpression effectively inhibited MAPK/ERK signaling, cell proliferation, migration, and invasion and increased the cell apoptosis of melanoma cells. In addition, we found that miR-596 directly targets MEK1 and two apoptotic proteins, MCL1, and BCL2L1, in melanoma cells. Our findings indicated that miR-596 is an important miRNA that both negatively regulates the MAPK/ERK signaling pathway by targeting MEK1 and modulates the apoptosis pathway by targeting MCL1 and BCL2L1, suggesting that miR-596 could be a therapeutic candidate for treating melanoma, and a prognostic factor for melanoma patients.
引用
- Liu SM, Lin CH, Lu J, et al. miR-596 Modulates Melanoma Growth by Regulating Cell Survival and Death. J Invest Dermatol. 2017. PMID: 29183729. doi:10.1016/j.jid.2017.11.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。